Literature DB >> 15749706

Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules.

Catherine X Moss1, Stephen P Matthews, Douglas J Lamont, Colin Watts.   

Abstract

Post-translational protein modifications can be recognized by B and T lymphocytes and can potentially make "self"-proteins appear foreign to the immune system. Such modifications may directly affect major histocompatibility complex-restricted T cell recognition of processed peptides or may perturb the processing events that generate such peptides. Using the tetanus toxin C fragment protein as a test case, we show that spontaneous deamidation of asparagine residues interferes with processing by the enzyme asparagine endopeptidase (AEP) and contributes to diminished antigen presentation. Deamidation inhibits AEP action either directly, when asparagine residues targeted by AEP are modified, or indirectly, when adjacent Asn residues are deamidated. Thus, deamidation of long-lived self-proteins may qualitatively or quantitatively affect the spectrum of self-peptides displayed to T cells and may thereby contribute to the onset or exacerbation of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749706     DOI: 10.1074/jbc.M501241200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Characterization of deamidation of barstar using electrospray ionization quadrupole time-of-flight mass spectrometry, which stabilizes an equilibrium unfolding intermediate.

Authors:  Santosh Kumar Jha; Putchen Dakshinamoorthy Deepalakshmi; Jayant B Udgaonkar
Journal:  Protein Sci       Date:  2012-03-16       Impact factor: 6.725

Review 2.  Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Authors:  Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

3.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

4.  Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain.

Authors:  Amy J Gleichman; Lynn A Spruce; Josep Dalmau; Steven H Seeholzer; David R Lynch
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

Review 5.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

6.  Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.

Authors:  Sandeep Kumar; Satish K Singh; Xiaoling Wang; Bonita Rup; Davinder Gill
Journal:  Pharm Res       Date:  2011-03-25       Impact factor: 4.200

7.  Deamidation Slows Curli Amyloid-Protein Aggregation.

Authors:  Hanliu Wang; Qin Shu; Carl Frieden; Michael L Gross
Journal:  Biochemistry       Date:  2017-05-26       Impact factor: 3.162

Review 8.  Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides.

Authors:  Hongqian Yang; Roman A Zubarev
Journal:  Electrophoresis       Date:  2010-06       Impact factor: 3.535

9.  Posttranslational Protein Modifications in Type 1 Diabetes - Genetic Studies with PCMT1, the Repair Enzyme Protein Isoaspartate Methyltransferase (PIMT) Encoding Gene.

Authors:  Ana M Wägner; Paul Cloos; Regine Bergholdt; Stefanie Eising; Caroline Brorsson; Martin Stalhut; Stephan Christgau; Jørn Nerup; Flemming Pociot
Journal:  Rev Diabet Stud       Date:  2009-02-10

Review 10.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.